Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04EEU
|
|||
| Former ID |
DNC000518
|
|||
| Drug Name |
Dazoxiben
|
|||
| Synonyms |
DAZOXIBEN; 78218-09-4; Dazoxibene; Dazoxiben [INN-Spanish]; Dazoxibenum; Dazoxibenum [INN-Latin]; Dazoxibene [INN-French]; Dazoxiben [INN:BAN]; 4-(2-(1H-Imidazol-1-yl)ethoxy)benzoic acid; UNII-09ZFC7974Q; 4-(2-imidazol-1-ylethoxy)benzoic acid; UK 37248; Benzoic acid, 4-(2-(1H-imidazol-1-yl)ethoxy)-; p-(2-Imidazol-1-ylethoxy)benzoic acid; 4-(2-(1-Imidazolyl)ethoxy)benzoesaeure; UK-37248; CHEMBL267473; 103735-00-8; 4-[2-(1H-imidazol-1-yl)ethoxy]benzoic acid; 09ZFC7974Q; AH-P 719 (9CI); NCGC00018938-03
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H12N2O3
|
|||
| Canonical SMILES |
C1=CC(=CC=C1C(=O)O)OCCN2C=CN=C2
|
|||
| InChI |
1S/C12H12N2O3/c15-12(16)10-1-3-11(4-2-10)17-8-7-14-6-5-13-9-14/h1-6,9H,7-8H2,(H,15,16)
|
|||
| InChIKey |
XQGZSYKGWHUSDH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 78218-09-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
6464175, 8182878, 11108723, 11138618, 16885502, 34717149, 46506407, 47927333, 50065204, 50101662, 50104198, 50483402, 57313477, 81041103, 90484147, 103167962, 104171390, 104301059, 118313769, 124884287, 125357718, 126684376, 129725579, 131326443, 132154930, 134223649, 134339926, 135049275, 135143057, 137021274, 141563666, 144204410, 160966204, 162178976, 162277685, 162770661, 163693520, 164788305, 165445590, 172886732, 178101865, 179071730, 186019504, 198967903, 206246230, 223681589, 223704361, 224873128, 226402235, 252347854
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thromboxane-A synthase (TBXAS1) | Target Info | Inhibitor | [1] |
| BioCyc | C20 prostanoid biosynthesis | |||
| KEGG Pathway | Arachidonic acid metabolism | |||
| Metabolic pathways | ||||
| Platelet activation | ||||
| Pathwhiz Pathway | Arachidonic Acid Metabolism | |||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| Arachidonic acid metabolism | ||||
| Phase 1 - Functionalization of compounds | ||||
| Eicosanoid Synthesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Metabolic protection of the reperfused canine endocardium by the thromboxane synthetase inhibitor, dazoxiben. Prostaglandins Leukot Essent Fatty Acids. 1988 Jul;33(1):13-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.